Gastroepiploic vascularized lymph node transfer for the treatment of extremity lymphedema: comparison between middle and distal inset.
Abstract
[BACKGROUND] Middle and distal insets of gastroepiploic vascularized lymph node transfer (GE-VLNT) for extremity lymphedema have been described. However, there has been no prior comparison of surgical or patient-reported outcomes between these techniques. We analyzed the outcomes between both insets in patients with extremity lymphedema.
[METHODS] Retrospective review of patients with extremity-lymphedema who underwent GE-VLNT. Two groups were analyzed: middle and distal recipient inset. We analyzed 6-month surgical and patient-reported outcomes using the Lymphedema Life Impact Scale-v2 (LLISv2) and scar satisfaction utilizing the Patient Scar Assessment Questionnaire (PSAQ).
[RESULTS] Between 2017 and 2019, 26 patients with stage II unilateral extremity lymphedema underwent laparoscopically-harvested GE-VLNT (13 distal and 13 middle inset). There were no differences in patient demographics between groups. Mean hospital stay for patients with upper extremity lymphedema was 1.3 4.0 days (P<0.05), and for lower extremity lymphedema was 1.0 4.5 days (P<0.05), middle distal inset, respectively. Mean return to daily activities for patients with upper extremity lymphedema was 13.4 33.4 days (P<0.05), and for lower extremity lymphedema was 16.0 29.5 days (P<0.05), middle distal inset, respectively. Both middle and distal inset showed significant mean excess volume reduction at 6 months postoperatively for both upper and lower extremity lymphedema (upper extremity: middle inset 23.3%, distal inset: 22.0%; lower extremity: middle inset 23.3% and distal inset 13.3%). LLISv2 scores showed improved functional outcomes postoperatively in both upper and lower extremity lymphedema with both insets. Scar satisfaction with appearance and symptoms was higher with middle inset (P<0.05).
[CONCLUSIONS] GE-VLNT is an effective surgical treatment for extremity lymphedema. The middle placement showed shorter hospital stay, early return to work and higher patient satisfaction.
[METHODS] Retrospective review of patients with extremity-lymphedema who underwent GE-VLNT. Two groups were analyzed: middle and distal recipient inset. We analyzed 6-month surgical and patient-reported outcomes using the Lymphedema Life Impact Scale-v2 (LLISv2) and scar satisfaction utilizing the Patient Scar Assessment Questionnaire (PSAQ).
[RESULTS] Between 2017 and 2019, 26 patients with stage II unilateral extremity lymphedema underwent laparoscopically-harvested GE-VLNT (13 distal and 13 middle inset). There were no differences in patient demographics between groups. Mean hospital stay for patients with upper extremity lymphedema was 1.3 4.0 days (P<0.05), and for lower extremity lymphedema was 1.0 4.5 days (P<0.05), middle distal inset, respectively. Mean return to daily activities for patients with upper extremity lymphedema was 13.4 33.4 days (P<0.05), and for lower extremity lymphedema was 16.0 29.5 days (P<0.05), middle distal inset, respectively. Both middle and distal inset showed significant mean excess volume reduction at 6 months postoperatively for both upper and lower extremity lymphedema (upper extremity: middle inset 23.3%, distal inset: 22.0%; lower extremity: middle inset 23.3% and distal inset 13.3%). LLISv2 scores showed improved functional outcomes postoperatively in both upper and lower extremity lymphedema with both insets. Scar satisfaction with appearance and symptoms was higher with middle inset (P<0.05).
[CONCLUSIONS] GE-VLNT is an effective surgical treatment for extremity lymphedema. The middle placement showed shorter hospital stay, early return to work and higher patient satisfaction.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 해부 | upper extremity lymphedema
|
scispacy | 1 | ||
| 합병증 | lymphedema
|
scispacy | 1 | ||
| 합병증 | scar
|
scispacy | 1 | ||
| 합병증 | upper extremity
|
scispacy | 1 | ||
| 약물 | [BACKGROUND] Middle
|
scispacy | 1 | ||
| 약물 | [RESULTS]
|
scispacy | 1 | ||
| 약물 | [CONCLUSIONS] GE-VLNT
|
scispacy | 1 | ||
| 질환 | extremity lymphedema
|
scispacy | 1 | ||
| 질환 | upper extremity lymphedema was 1.3 4.0 days (P<0.05), and for lower extremity lymphedema was 1.0 4.5 days (P<0.05), middle distal inset, respectively.
|
scispacy | 1 | ||
| 질환 | upper extremity lymphedema
|
scispacy | 1 | ||
| 질환 | lower extremity lymphedema
|
C1275454
Lymphedema of lower extremity
|
scispacy | 1 | |
| 질환 | Scar
|
scispacy | 1 | ||
| 기타 | Gastroepiploic
|
scispacy | 1 | ||
| 기타 | lymph node
|
scispacy | 1 | ||
| 기타 | patients
|
scispacy | 1 | ||
| 기타 | Scale-v2
|
scispacy | 1 | ||
| 기타 | Patient Scar
|
scispacy | 1 | ||
| 기타 | patient
|
scispacy | 1 |